Correction to: Potential cost-savings from the use of the biosimilars filgrastim, infliximab and insulin glargine in Canada: a retrospective analysis
In the original publication of this article [1], there is a mistake in the Fig. 2a, 2b, and 2c.
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2019-12-01
|
| Series: | BMC Health Services Research |
| Online Access: | https://doi.org/10.1186/s12913-019-4829-z |